Antonio Sahuquillo-Torralba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonio Sahuquillo-Torralba has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Mar Llamas-Velasco
Department of Dermatology Hospital Universitario de la Princesa Madrid Spain
11 shared publications - Esteban Daudén
Department of Dermatology Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS‐IP) Madrid Spain
9 shared publications - Isabel Belinchón
Department of Clinical Medicine, Miguel Hernández University, 03550 Alicante, Spain
8 shared publications - Raquel Rivera Diaz
Department of Dermatology Hospital Universitario 12 de Octubre, Universidad Complutense Madrid Spain
7 shared publications - Jose Manuel Carrascosa
Departamento de Dermatología, Hospital Universitari Germans Trias i Pujol. Germans Trias I Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona, Badalona, Barcelona, España
6 shared publications - Pablo de la Cueva
Department of Dermatology, Hospital General Universitario Gregorio Marañon, Madrid, Spain
6 shared publications
Latest Publications
- Open Access
Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)
Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug’s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.
Open AccessReal-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)
Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug’s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.
- Open Access
- 28 May 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (7) , T703-T730
[Translated article] Expert Recommendations on Topical Therapy for Psoriasis from the Spanish Psoriasis Working Group (GPS)
- 28 May 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (7) , T703-T730
Open Access[Translated article] Expert Recommendations on Topical Therapy for Psoriasis from the Spanish Psoriasis Working Group (GPS)
- 19 May 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (9) , 1643-1655
Risk of adverse events of psoriasis treatment with biologic agents and new small molecules—BIOBADADERM Registry
Background: Registry studies are needed to provide comprehensive and updated assessments of the long‐term safety profiles of systemic drugs in psoriasis.Objectives: To analyse the safety of biologic drugs and new oral molecules used for the treatment of moderate‐to‐severe psoriasis in patients included in the Spanish Registry of Adverse Events of Biological Therapy (BIOBADADERM), compared to that of adalimumab.Methods: Prospective, multicentre cohort of patients with psoriasis. The safety profiles of biologic agents (etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab and tildrakizumab), apremilast and dimethyl fumarate were studied. The incidence rate ratio (IRR) and adjusted IRR of specific adverse events were assessed for each drug, using adalimumab as a reference. Propensity scores were used to adjust for selection bias.Results: Our study included 4212 patients (7590 treatment cycles; 17,284 patient‐years of follow‐up). Adalimumab had an incidence rate for all adverse events of 614 per 1000 patient‐years (95% confidence interval [CI] (591; 637)). The risk of all adverse events was significantly lower for guselkumab (adjusted IRR [aIRR] 0.56, 95% CI (0.47; 0.67)), risankizumab (aIRR 0.59, 95% CI (0.48; 0.71)), tildrakizumab [aIRR 0.6, 95% CI (0.46; 0.8)], ixekizumab (aIRR 0.65, 95% CI (0.56; 0.76)) and ustekinumab (aIRR 0.73 95% CI (0.65; 0.82)) compared to adalimumab (p ≤ 0.002), as well as the risk for some specific organ‐based groups of adverse events. Conversely, the risk for all adverse events was significantly higher for dimethyl fumarate (aIRR 3.67, 95% CI (2.71; 4.97)), infliximab (aIRR 1.88, 95% CI (1.45; 2.43)) (p ≤ 0.002) and apremilast (aIRR 1.27, 95% CI (1.05; 1.53)) (p 0.012). The risk of malignant neoplasms was significantly reduced in the group treated with ixekizumab (aIRR 0.14 95% CI (0.04; 0.47)).Conclusions: Our data support that, overall, the new biologic treatments have a superior safety profile in real‐world practice compared to adalimumab and its biosimilars.
- 19 May 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (9) , 1643-1655
Risk of adverse events of psoriasis treatment with biologic agents and new small molecules—BIOBADADERM Registry
Background: Registry studies are needed to provide comprehensive and updated assessments of the long‐term safety profiles of systemic drugs in psoriasis.Objectives: To analyse the safety of biologic drugs and new oral molecules used for the treatment of moderate‐to‐severe psoriasis in patients included in the Spanish Registry of Adverse Events of Biological Therapy (BIOBADADERM), compared to that of adalimumab.Methods: Prospective, multicentre cohort of patients with psoriasis. The safety profiles of biologic agents (etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab and tildrakizumab), apremilast and dimethyl fumarate were studied. The incidence rate ratio (IRR) and adjusted IRR of specific adverse events were assessed for each drug, using adalimumab as a reference. Propensity scores were used to adjust for selection bias.Results: Our study included 4212 patients (7590 treatment cycles; 17,284 patient‐years of follow‐up). Adalimumab had an incidence rate for all adverse events of 614 per 1000 patient‐years (95% confidence interval [CI] (591; 637)). The risk of all adverse events was significantly lower for guselkumab (adjusted IRR [aIRR] 0.56, 95% CI (0.47; 0.67)), risankizumab (aIRR 0.59, 95% CI (0.48; 0.71)), tildrakizumab [aIRR 0.6, 95% CI (0.46; 0.8)], ixekizumab (aIRR 0.65, 95% CI (0.56; 0.76)) and ustekinumab (aIRR 0.73 95% CI (0.65; 0.82)) compared to adalimumab (p ≤ 0.002), as well as the risk for some specific organ‐based groups of adverse events. Conversely, the risk for all adverse events was significantly higher for dimethyl fumarate (aIRR 3.67, 95% CI (2.71; 4.97)), infliximab (aIRR 1.88, 95% CI (1.45; 2.43)) (p ≤ 0.002) and apremilast (aIRR 1.27, 95% CI (1.05; 1.53)) (p 0.012). The risk of malignant neoplasms was significantly reduced in the group treated with ixekizumab (aIRR 0.14 95% CI (0.04; 0.47)).Conclusions: Our data support that, overall, the new biologic treatments have a superior safety profile in real‐world practice compared to adalimumab and its biosimilars.
- 30 April 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (9) , 1631-1642
Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry
Background: Psoriasis is a chronic inflammatory disease with multiple comorbidities, including an increased risk of major adverse cardiovascular events (MACE). There is limited and contradictory evidence comparing the impact of systemic treatments for psoriasis on MACE.Objectives: To evaluate the incidence of MACE associated with each systemic treatment used for patients with psoriasis and compare these rates to those observed with methotrexate (MTX).Methods: We conducted a prospective cohort study using data from the BIOBADADERM registry. Propensity score matching was used to adjust for baseline differences between treatment groups. We calculated the incidence rate (IR) of MACE for each systemic treatment class, including biologics (anti‐TNF, IL‐12/23, IL‐17 and IL‐23 inhibitors), conventional systemic therapies (MTX, cyclosporine, dimethyl fumarate and acitretin) and apremilast (APR). The IR for each group was compared to those observed in patients treated with MTX using Poisson regression models adjusted for potential confounders, with 95% confidence intervals (95% CI). The primary outcome was the adjusted incidence rate ratios (IRR) for MACE between patients receiving MTX and those receiving another systemic treatment.Results: We analysed data from 5622 patients, 11,368 treatment cycles and 21,762 person‐years (PYs). APR (IRR = 0.17; 95% CI, 0.04–0.70) and IL‐17 (IRR = 0.43; 95% CI, 0.20–0.91) were associated with a significant reduction in the risk of MACE compared to MTX. Cyclosporine was associated with an increased risk of MACE (IRR = 3.59; 95% CI, 1.17–10.99) compared to MTX. The remaining systemic psoriasis treatments were not significantly associated with an increased or decreased risk of MACE.Conclusions: This real‐world evidence study indicates a potential association between APR and IL‐17 with a lower incidence of MACE, while CYC showed a higher incidence compared to MTX. These findings underscore the importance of considering cardiovascular outcomes when selecting systemic therapies for patients with psoriasis.
- 30 April 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (9) , 1631-1642
Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry
Background: Psoriasis is a chronic inflammatory disease with multiple comorbidities, including an increased risk of major adverse cardiovascular events (MACE). There is limited and contradictory evidence comparing the impact of systemic treatments for psoriasis on MACE.Objectives: To evaluate the incidence of MACE associated with each systemic treatment used for patients with psoriasis and compare these rates to those observed with methotrexate (MTX).Methods: We conducted a prospective cohort study using data from the BIOBADADERM registry. Propensity score matching was used to adjust for baseline differences between treatment groups. We calculated the incidence rate (IR) of MACE for each systemic treatment class, including biologics (anti‐TNF, IL‐12/23, IL‐17 and IL‐23 inhibitors), conventional systemic therapies (MTX, cyclosporine, dimethyl fumarate and acitretin) and apremilast (APR). The IR for each group was compared to those observed in patients treated with MTX using Poisson regression models adjusted for potential confounders, with 95% confidence intervals (95% CI). The primary outcome was the adjusted incidence rate ratios (IRR) for MACE between patients receiving MTX and those receiving another systemic treatment.Results: We analysed data from 5622 patients, 11,368 treatment cycles and 21,762 person‐years (PYs). APR (IRR = 0.17; 95% CI, 0.04–0.70) and IL‐17 (IRR = 0.43; 95% CI, 0.20–0.91) were associated with a significant reduction in the risk of MACE compared to MTX. Cyclosporine was associated with an increased risk of MACE (IRR = 3.59; 95% CI, 1.17–10.99) compared to MTX. The remaining systemic psoriasis treatments were not significantly associated with an increased or decreased risk of MACE.Conclusions: This real‐world evidence study indicates a potential association between APR and IL‐17 with a lower incidence of MACE, while CYC showed a higher incidence compared to MTX. These findings underscore the importance of considering cardiovascular outcomes when selecting systemic therapies for patients with psoriasis.
- Open Access
- 8 March 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (7) , 703-730
Tratamiento tópico de la psoriasis: recomendaciones de expertos del Grupo Español de Psoriasis (GPS)
- 8 March 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (7) , 703-730
Open AccessTratamiento tópico de la psoriasis: recomendaciones de expertos del Grupo Español de Psoriasis (GPS)
- Open Access
- 1 November 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (6) , 922-927
Guselcumabe, risanquizumabe e tildraquizumabe demonstram eficácia e segurança semelhantes no tratamento da psoríase: estudo comparativo direto na prática clínica
- 1 November 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (6) , 922-927
Open AccessGuselcumabe, risanquizumabe e tildraquizumabe demonstram eficácia e segurança semelhantes no tratamento da psoríase: estudo comparativo direto na prática clínica
- Open Access
- 10 August 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (6) , 922-927
Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice
- 10 August 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (6) , 922-927
Open AccessGuselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice
- 26 June 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (11) , 1455-1457
Treatment of palmoplantar psoriasis with oral roflumilast: a case series
Palmoplantar psoriasis (PP) is a particular type of psoriasis that can justify systemic treatment. Roflumilast is a targeted inhibitor of phosphodiesterase-4 that has been recently approved by the US Food and Drugs Administration as a cream for the treatment of plaque psoriasis. In a small randomized clinical trial and single case reports, oral roflumilast has demonstrated efficacy in the treatment of plaque psoriasis. To the best of our knowledge, we present the first case series of patients with PP treated with oral roflumilast.
- 26 June 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (11) , 1455-1457
Treatment of palmoplantar psoriasis with oral roflumilast: a case series
Palmoplantar psoriasis (PP) is a particular type of psoriasis that can justify systemic treatment. Roflumilast is a targeted inhibitor of phosphodiesterase-4 that has been recently approved by the US Food and Drugs Administration as a cream for the treatment of plaque psoriasis. In a small randomized clinical trial and single case reports, oral roflumilast has demonstrated efficacy in the treatment of plaque psoriasis. To the best of our knowledge, we present the first case series of patients with PP treated with oral roflumilast.
- 28 December 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (9) , 1783-1790
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice
Background: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.Objective: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.Methods: We studied 180 SNPs in patients with moderate‐to‐severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed.Results: A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR‐146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83–0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes.Conclusion: We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non‐response to this drug in patients with plaque psoriasis.
- 28 December 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (9) , 1783-1790
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice
Background: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.Objective: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.Methods: We studied 180 SNPs in patients with moderate‐to‐severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed.Results: A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR‐146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83–0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes.Conclusion: We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non‐response to this drug in patients with plaque psoriasis.
- 12 July 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (4) , e317-e326
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Background and Objective: The data in clinical practice regarding the effectiveness and safety of brodalumab in psoriasis are scarce, especially at scalp and palmoplantar locations. The main objective was the percentage of patients achieving absolute PASI ≤3/ ≤1/ =0 for plaque psoriasis and the percentage of patients achieving an IGA 0‐1/IGA 0 for the special locations at Week 52 of treatment.Patients and Methods: Observational retrospective multicentre study in 28 Spanish Hospitals that included adult patients with plaque psoriasis treated with brodalumab, from September 2018 until March 2021.Results: A total of 200 patients were included. The mean baseline PASI was 10.97 (±6.28) with a mean basal scalp (n = 58) and palmoplantar (n = 40) IGA of 2.10 (±0.97) and 2.15 (±1.26), respectively. At Week 52, 93.98%/75.90%/68.67% of patients reached an absolute PASI ≤3/ ≤1/ =0 in plaque psoriasis (n = 83), with a percentage of patients achieving scalp (n = 27) and palmoplantar (n = 19) IGA 0‐1/IGA 0 of 96.3%/88.9% and 100%/88.9%, respectively. Fifteen per cent of patients reported any adverse events with candidiasis being the most reported (6%), but only 6% of the adverse events required the withdrawal.Conclusions: Brodalumab demonstrated high PASI and IGA responses and was well tolerated in clinical practice in plaque, scalp and palmoplantar psoriasis.
- 12 July 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (4) , e317-e326
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Background and Objective: The data in clinical practice regarding the effectiveness and safety of brodalumab in psoriasis are scarce, especially at scalp and palmoplantar locations. The main objective was the percentage of patients achieving absolute PASI ≤3/ ≤1/ =0 for plaque psoriasis and the percentage of patients achieving an IGA 0‐1/IGA 0 for the special locations at Week 52 of treatment.Patients and Methods: Observational retrospective multicentre study in 28 Spanish Hospitals that included adult patients with plaque psoriasis treated with brodalumab, from September 2018 until March 2021.Results: A total of 200 patients were included. The mean baseline PASI was 10.97 (±6.28) with a mean basal scalp (n = 58) and palmoplantar (n = 40) IGA of 2.10 (±0.97) and 2.15 (±1.26), respectively. At Week 52, 93.98%/75.90%/68.67% of patients reached an absolute PASI ≤3/ ≤1/ =0 in plaque psoriasis (n = 83), with a percentage of patients achieving scalp (n = 27) and palmoplantar (n = 19) IGA 0‐1/IGA 0 of 96.3%/88.9% and 100%/88.9%, respectively. Fifteen per cent of patients reported any adverse events with candidiasis being the most reported (6%), but only 6% of the adverse events required the withdrawal.Conclusions: Brodalumab demonstrated high PASI and IGA responses and was well tolerated in clinical practice in plaque, scalp and palmoplantar psoriasis.